Assessing the impact of head-mounted virtual reality (VR) devices in the ICU setting: a mixed methods study on patient outcomes and perspectives

Assessing the impact of head-mounted virtual reality (VR) devices in the ICU setting: a mixed methods study on patient outcomes and perspectives - Research on the application of head-mounted virtual reality (VR) devices in ICU environment

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500098279

Enrollment

Unknown

Registered

2025-03-05

Start date

2024-11-04

Completion date

Unknown

Last updated

2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mixed anxiety and depressive disorder

Interventions

Control group:Routine ICU care is adopted, which mainly includes monitoring vital signs, symptomatic treatment, nutritional support, basic nursing, position management, routine rehabilitation, etc. ac

Experimental Group:The experimental group adopted a VR intervention program based on the control group.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Age between 18 and 65 years. (2)In the recovery phase and expected to remain in the ICU for over 3 days. (3) Conscious and Richmond Agitation-Sedation Scale score of 0. (4) Non-mechanically ventilated . (5) Normal auditory and visual functions . (6) Not currently taking anti-anxiety or antidepressant medications. (7) No head or facial trauma or wounds, able to wear VR devices smoothly. (8) Patients capable of effective communication with stuffs through language or text. (9) A score of 5 or above on the GAD-7 or PHQ-9.. (10) NPRS <=7 points (mild or moderate pain level). (11) Voluntary participation in the study.

Exclusion criteria

Exclusion criteria: (1) Known allergies or sensitivities to VR equipment (Rousseaux et al., 2022). (2) Experienced significant medical condition changes or consciousness disorders during the study period. (3) Pregnant women. (4) Diagnosed with delirium following assessment using the CAM-ICU. (5) Any contraindications to the use of virtual reality technology, such as a history of severe motion sickness or epilepsy. (6) Requires high doses of vasopressors or sedatives/analgesics. (7) Participation in other interventional trials.

Design outcomes

Primary

Measure	Time frame
Generalized Anxiety Disorder 7-item scale;Patient Health Questionnaire-9;Numeric Pain Rating Scale;Confusion Assessment Method for the Intensive Care Unit;Montreal Cognitive Assessment;	—

Countries

China

Contacts

Public ContactHuang Debin

The First Affiliated Hospital of Guangxi Medical University

hdeb@sina.com+86 138 7814 8875

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026